What Is a Spindle Cell Tumor? Types & Treatments

A spindle cell tumor is any growth made up of elongated, cigar-shaped cells that taper at each end, giving them a spindle-like silhouette under the microscope. The term describes how the cells look, not how the tumor behaves, which is why it covers a surprisingly wide range of conditions: harmless lumps that never return after removal, slow-growing masses that invade nearby tissue but do not spread, and outright cancers capable of metastasizing to distant organs. Pinning down which category a specific spindle cell tumor falls into is one of the harder problems in surgical pathology, and it shapes every decision that follows.

Why the Name Refers to Shape, Not Behavior

When a pathologist examines a tissue sample and sees cells that are long and narrow, arranged in sweeping bundles or interlocking whorls, the immediate shorthand is “spindle cell.” These cells typically form interlacing fascicles, sometimes crossing each other at wide angles in a pattern sometimes described as herring-bone or storiform (pinwheel-like).¹ That description tells you how the cells are shaped but almost nothing about whether the growth is dangerous. A completely benign nerve sheath tumor (schwannoma), a borderline-aggressive desmoid tumor, and a full-blown sarcoma can all present this way. The diagnostic challenge is separating those possibilities once you have a piece of tissue.

The Spectrum From Benign to Malignant

Spindle cell tumors break roughly into three tiers of clinical concern.

Benign spindle cell tumors include schwannomas, leiomyomas (smooth-muscle growths like uterine fibroids), myofibroblastomas, spindle cell lipomas, and solitary fibrous tumors, among others. Nodular fasciitis, a fast-growing but self-limiting lump that sometimes alarmed both patients and doctors, is also in this category. These growths tend to be well defined, rarely recur after complete removal, and carry no risk of spreading.² Gastric schwannomas, for example, are slow-growing and essentially cured with complete excision.³

Intermediate tumors sit in an uncomfortable gray zone. Desmoid-type fibromatosis is the most familiar example: these tumors grow aggressively into surrounding tissue and have a high rate of coming back after surgery, but they do not metastasize.⁴ A literature review found about a 29% overall recurrence rate for desmoid tumors, with the risk climbing to 50% when the tumor was only partially removed.⁴ Other intermediate-grade entities include dermatofibrosarcoma protuberans and inflammatory myofibroblastic tumors.

Malignant spindle cell tumors are the sarcomas. Sarcomas as a whole are uncommon, representing less than 1% of adult cancers, and spindle cell sarcomas are one subset within that already-rare group.⁵ Their rarity complicates both diagnosis and research, because large clinical trials are difficult to assemble.

Common Types and Where They Arise

Spindle cell tumors pop up in almost every organ system, but certain types cluster in specific locations.

Gastrointestinal Stromal Tumors (GISTs)

GISTs are the most common mesenchymal tumors of the gastrointestinal tract.⁶ They typically arise in the stomach or small intestine and are driven by mutations in one of two genes: about three-quarters carry KIT mutations, roughly 10% carry PDGFRA mutations, and the remaining 15% have other genetic drivers, including changes in genes like BRAF and the succinate dehydrogenase complex.⁷ An interesting detail from earlier research is that KIT mutations appear preferentially in GISTs with a spindle cell appearance rather than in the epithelioid (rounder-celled) subtype.⁸ This link between genetics and cell shape turns out to matter for treatment, because GISTs with KIT mutations tend to respond well to targeted drugs like imatinib.

Uterine Leiomyosarcoma

Leiomyosarcoma, a cancer of smooth muscle, is the most common soft tissue sarcoma in adults.⁹ When it arises in the uterus, it accounts for roughly 2% to 5% of uterine cancers. Despite the fact that most patients are diagnosed at an early stage, uterine leiomyosarcoma carries a poor prognosis because it tends to resist standard treatments.⁹ The spindle cell variant is by far the most common subtype, found in over 80% of cases, and it actually carries a somewhat better outlook than the epithelioid or myxoid variants, with a median overall survival of about 77 months compared with 49 months for the non-spindle forms.¹⁰

One of the clinical dilemmas here is that the uterus is also home to benign leiomyomas (fibroids), which are extremely common. Distinguishing a leiomyosarcoma from a fibroid before surgery is difficult, and pathologists face overlapping features when spindle cells are involved. Immunohistochemical markers like BCOR, Cyclin D1, and CD10 are being studied to help separate endometrial stromal sarcomas from other uterine spindle cell lesions.¹¹

Spindle Cell Tumors of the Skin

The skin hosts its own crowded lineup of spindle cell diagnoses, including atypical fibroxanthoma, spindle cell squamous cell carcinoma, desmoplastic melanoma, and dermatofibrosarcoma protuberans. These look deceptively alike under the microscope, which is a real clinical problem because their treatments and prognoses diverge sharply. Spindle cell melanoma, in particular, can lack pigment entirely (amelanotic), making it easy to mistake for something else.¹² Immunohistochemistry panels are essential for sorting these out; for instance, CD10 staining strongly favors a diagnosis of atypical fibroxanthoma over spindle cell squamous cell carcinoma or melanoma.¹³

Malignant Peripheral Nerve Sheath Tumors

Malignant peripheral nerve sheath tumors (MPNSTs) are high-grade sarcomas that arise from the cells surrounding nerves. They are strongly associated with neurofibromatosis type 1, a genetic condition that carries an estimated 8% to 13% lifetime risk of developing one of these tumors.¹⁴ Imaging studies suggest that in most cases, the cancer arises from a distinct pre-existing nodular lesion in a nerve that eventually transforms.¹⁵

How Spindle Cell Tumors Are Diagnosed

A biopsy is always the starting point. But under routine staining, many spindle cell tumors look similar enough that the tissue sample alone cannot seal the diagnosis. Pathologists rely heavily on immunohistochemistry, a technique that uses antibodies targeting specific proteins to reveal what kind of cell produced the tumor.

Panels of markers are selected based on the clinical scenario. In the skin, p75 nerve growth factor receptor stains all spindle cell melanomas while being negative in most other spindle cell skin cancers, outperforming the older S100 marker in sensitivity.¹⁶ In the chest, cytokeratin staining helps separate sarcomatoid mesotheliomas (which express it) from sarcomas (which generally do not).¹⁷ In the ovary, inhibin can distinguish a sarcomatoid granulosa cell tumor from other spindle cell lesions.¹⁸ Different organs, different panels, but the logic is the same: stack enough markers to narrow the field.

Molecular testing has increasingly become a second essential layer. Gene fusion analysis through RNA sequencing can identify fusions involving NTRK, RET, BRAF, and EWSR1 genes, each of which points toward a specific diagnosis. Spindle cell tumors harboring RET fusions, for example, display a range of appearances that can overlap morphologically with NTRK-rearranged tumors, making molecular confirmation the only way to tell them apart definitively.¹⁹ Novel BRAF fusions and activating mutations have been identified in spindle cell sarcomas that look like infantile fibrosarcoma, a discovery that expands the molecular landscape considerably.²⁰ In pediatric tumors, NTRK gene rearrangements are shared across several entities, including infantile fibrosarcoma and the recently described lipofibromatosis-like neural tumor, making genetic testing crucial for distinguishing them.²¹

Known Risk Factors

Most spindle cell tumors arise without a clear cause, but a few risk factors are well established.

Genetic syndromes carry the strongest known risk. Neurofibromatosis type 1 dramatically raises the odds of developing MPNSTs, as noted above. Familial adenomatous polyposis is associated with desmoid tumors. Li-Fraumeni syndrome, caused by inherited TP53 mutations, increases the risk of sarcomas generally.

Prior radiation therapy is a recognized trigger for spindle cell sarcomas. Most radiation-induced sarcomas appear after doses above 55 Gray, though they have been reported at lower exposures as well.²² These tumors tend to develop years to decades after treatment. One reported case involved a patient who developed an undifferentiated spindle cell sarcoma at the original treatment site five years after brachytherapy for tongue cancer.²³ Another developed a spindle cell sarcoma of the jaw 21 years after radiation for childhood retinoblastoma.²² These cases are uncommon, but they underscore why oncologists track patients long after radiation treatment ends.

Treatment Approaches

Surgery remains the cornerstone for most spindle cell tumors, benign and malignant alike. The goal is to remove the tumor with a margin of healthy tissue around it, though how much margin is needed depends on grade and context. For low-grade soft tissue sarcomas, data suggest that a surgical margin of at least 2 mm provides good local control and helps prevent distant spread.²⁴ For high-grade tumors, having an intact natural barrier like muscle fascia or bone lining at the margin appears to improve outcomes more than margin width alone, especially when adjuvant radiation and chemotherapy are added.²⁴ Separate recommendations for high-grade pleomorphic sarcomas of the extremities suggest minimum safe clearances of about 5 mm without radiation or 1 mm when radiation therapy is given afterward.²⁵

Limb-sparing surgery is the norm for extremity sarcomas now, having largely replaced amputation. But it comes with functional trade-offs. Patients who require bone removal during limb salvage score about 20% lower on functional recovery measures than those who do not, even when recovery time is accounted for.²⁶ Rehabilitation planning is therefore an important part of the treatment conversation, particularly for tumors near joints or major nerves.

When surgery alone is not sufficient or when tumors recur, other options come into play. Conventional chemotherapy for advanced soft tissue sarcomas relies on drugs like anthracyclines and alkylating agents, but their benefit beyond the first line of treatment is limited; across high-grade subtypes, median overall survival for metastatic disease hovers around 12 to 18 months.²⁷ That sobering number has driven interest in more targeted approaches.

Targeted Therapy and the Rise of Molecular Matching

The clearest success story in targeted therapy for spindle cell tumors is imatinib for GISTs. Because the majority of GISTs are fueled by a specific mutation in KIT or PDGFRA, blocking those proteins with a tyrosine kinase inhibitor transformed a previously treatment-resistant cancer into a manageable one for many patients. That model, find the mutation and match the drug, has since expanded.

NTRK gene fusions, found across several spindle cell tumor types in both children and adults, can be targeted with TRK inhibitors like larotrectinib and entrectinib. A case of a pediatric low-grade spindle cell sarcoma with an NTRK rearrangement illustrated the potential: early identification of the fusion enabled timely TRK inhibitor therapy, producing durable disease control and functional recovery.²⁸ The same logic applies to RET fusions, which retain a druggable tyrosine kinase domain in the resulting fusion protein.¹⁹ The discovery of BRAF mutations and fusions in certain spindle cell sarcomas opens additional avenues, given that BRAF-targeted drugs are already available for other cancers.²⁰

This is why molecular testing matters so much in spindle cell tumors. Two tumors that look identical under a microscope may have completely different genetic drivers, and therefore completely different treatment options. Getting the molecular workup right is not an academic exercise; it can be the difference between a drug that works and one that does nothing.

Immunotherapy for Sarcomas

Checkpoint immunotherapy, which has transformed treatment for several common cancers, has been slower to make inroads in sarcomas. Most soft tissue sarcomas have relatively low mutation burdens, which limits the immune system’s ability to recognize them. However, some subgroups do respond. A study of anti-PD-1 therapy (pembrolizumab) in advanced sarcomas found that about 21% of patients had clinical benefit. Strikingly, patients whose sarcoma originated in the skin fared much better: 58% showed clinical benefit compared with 11% of those with non-cutaneous tumors, and median overall survival was roughly 19 months versus 9 months.²⁹ Where the tumor starts, in other words, may predict response to immunotherapy better than the specific histologic diagnosis does. Skin-origin sarcomas are more exposed to UV-driven mutations, which could make them more immunologically visible.

When the Diagnosis Is Uncertain

One of the most stressful aspects for patients is the diagnostic journey itself. Because so many spindle cell tumors look alike microscopically, initial biopsies sometimes yield ambiguous reports. A pathologist may describe “a spindle cell neoplasm” without being able to commit to a specific diagnosis right away, especially if the sample is small or the immunohistochemistry results are equivocal. This is not a failure. It reflects the genuine difficulty of the task, and it is far better than a premature wrong answer that leads to inappropriate treatment.

The practical takeaway: if you receive a pathology report describing a spindle cell tumor without a firm specific diagnosis, do not panic, but do insist on a thorough workup. That usually means additional immunohistochemistry, possible molecular testing, and ideally review at a center with sarcoma expertise. Second opinions in sarcoma pathology change the diagnosis in a meaningful fraction of cases, something that sarcoma specialists are well aware of and actively encourage.

Spindle Cell Tumors in Animals

Veterinary oncology faces parallel challenges. Soft tissue sarcomas are common in dogs, particularly in medium to large breeds and older animals. Like their human counterparts, these tumors are characterized by spindle cells with poorly defined margins, making them locally invasive with a high tendency to recur but relatively low rates of distant spread.³⁰ Chemotherapy response is poor, and wide surgical margins remain the primary tool, much as in humans. If your veterinarian mentions a “spindle cell tumor” in your dog, the diagnostic and treatment logic follows the same broad principles: biopsy for grading, wide excision when possible, and monitoring for recurrence.

Experimental and Less Common Treatments

For tumors that keep coming back after conventional surgery, some newer approaches are under investigation. High-intensity focused ultrasound (HIFU), which uses concentrated sound waves to heat and destroy tissue, has been reported as a salvage option in a case where a spindle cell sarcoma recurred despite multiple surgeries and radioactive implants. The HIFU treatment achieved complete ablation of the recurrent tumor, though bone damage at the treatment site was noted as a complication.³¹ This is a single case report, not a standard of care, but it illustrates the kind of creative multimodal thinking that refractory spindle cell sarcomas sometimes demand.

The EWSR1-PATZ1 gene fusion identifies yet another emerging diagnostic entity: a sarcoma with spindle and round cells that shows polyphenotypic differentiation, meaning the tumor cells express markers from multiple cell lineages simultaneously.³² These fusions are being catalogued and characterized so that treatment algorithms can eventually account for them, though targeted drugs for this specific fusion are not yet in clinical use. The landscape of molecularly defined spindle cell tumors keeps expanding, and with each new fusion or mutation identified, there is at least the possibility of a matched therapy down the line.